Study of continuous vaccination with epitope peptides for unresectable pancreatic cancer
- Conditions
- nresectable Pancreatic Cancer
- Registration Number
- JPRN-UMIN000009053
- Lead Sponsor
- Yamaguchi University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 60
Not provided
(1) Active double cancer (include asynchronous double cancer with disease-free duration <=1 year) except carcinoma in situ or intramucosal cancer. (2) Interstitial pneumonia or pulmonary fibrosis. (3) Severe nervous disorder or mental disorder. (4)History of myocardial infarction, severe unstable angina pectoris, CABG, congestive heart failure, cerebrovascular accident, pulmonary embolism, deep-vein thrombosis, or other severe thromboembolism within 12 months (5) Allergy for using epitope peptides (6)Unhealed traumatic lesion, including traumatic fracture. (7)Pregnant females or nursing mothers who can not stop lactation after the recruitment. (8)The subject who was determined by investigator that being not adequate to participate in the trial.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method